Y Intercept Hong Kong Ltd Takes $1.70 Million Position in Stryker Co. (NYSE:SYK)

Y Intercept Hong Kong Ltd purchased a new stake in Stryker Co. (NYSE:SYK) in the fourth quarter, Holdings Channel reports. The firm purchased 4,733 shares of the medical technology company’s stock, valued at approximately $1,704,000.

Several other hedge funds also recently added to or reduced their stakes in SYK. Dunhill Financial LLC grew its position in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the period. Centricity Wealth Management LLC purchased a new position in Stryker in the fourth quarter worth approximately $30,000. Darwin Wealth Management LLC purchased a new position in Stryker in the third quarter worth approximately $36,000. Activest Wealth Management purchased a new position in Stryker in the fourth quarter worth approximately $36,000. Finally, Crews Bank & Trust purchased a new position in Stryker in the fourth quarter worth approximately $39,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Stock Up 0.7 %

Stryker stock opened at $390.57 on Wednesday. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The stock has a market cap of $149.03 billion, a PE ratio of 50.33, a P/E/G ratio of 2.93 and a beta of 0.96. The stock’s fifty day moving average is $378.78 and its two-hundred day moving average is $370.22.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the company earned $3.46 EPS. On average, sell-side analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on SYK shares. Canaccord Genuity Group increased their price objective on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Robert W. Baird raised their price target on Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Barclays raised their price target on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Argus set a $450.00 price target on Stryker in a research report on Monday, February 3rd. Finally, StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a research note on Tuesday. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $422.15.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.